HAYWARD, Calif.--(BUSINESS WIRE)--IMPAX Laboratories, Inc. (OTC:IPXL) today announced that it and ALZA Corporation and McNeil-PPC have filed with the court a signed stipulation for the dismissal of a patent infringement lawsuit related to the Company’s Abbreviated New Drug Application (ANDA) for methylphenidate hydrocholoride ER, 18, 27, 36, 54 mg. tablets, generic of Concerta®. Alza Corporation and McNeil-PPC filed the suit against the Company last year in United States District Court for the District of Delaware. The Company’s ANDA remains under review by FDA as well as a Citizen’s Petition filed by McNeil relating to approval criteria for Concerta generics.
